CENPI Facilitates Breast Cancer Progression through Wnt/β-Catenin Modulation

Study Background and Research Question

Breast cancer (BCa) remains the most prevalent malignancy among women worldwide, responsible for approximately 2.3 million new cases and 665,000 deaths annually, representing 15.4% of female cancer-related mortality according to the reference study. While advances in surgery, chemotherapy, endocrine, and targeted therapies have improved patient outcomes, treatment resistance and disease heterogeneity continue to impede long-term survival. Chromosomal instability—a hallmark of many cancers and especially pronounced in triple-negative breast cancer—arises from errors in chromosome segregation during mitosis. Centromere integrity, maintained by centromere-associated proteins such as centromere protein I (CENPI), is critical for proper chromosome segregation. Though CENPI has been implicated in oncogenesis across various cancers, its functional and molecular roles in BCa remained unresolved.

Key Innovation from the Reference Study

Wu et al. (2025) systematically characterize the role of CENPI in breast cancer progression, demonstrating that CENPI acts as a potent oncogene by activating Wnt/β-catenin signaling. Their work not only links CENPI overexpression to tumor growth and poor prognosis in BCa but also deciphers the molecular mechanism by which CENPI drives malignancy. This study is among the first to directly connect centromere protein dysfunction with canonical Wnt pathway activation in breast cancer, highlighting CENPI as both a biomarker and a promising therapeutic target.

Methods and Experimental Design Insights

The research combined in silico, in vitro, and in vivo approaches to dissect CENPI’s role in BCa:

• Clinical data analysis: CENPI expression was examined using The Cancer Genome Atlas (TCGA) breast cancer dataset, complemented by immunohistochemical staining in human BCa tissue samples, to correlate CENPI levels with disease progression and survival.
• Functional assays: Manipulation of CENPI expression in BCa cell lines allowed assessment of changes in proliferation, migration, and tumorigenic potential. Animal xenograft models provided in vivo validation of these effects.
• Molecular mechanism exploration: RNA-sequencing and bioinformatics analyses identified downstream pathways affected by CENPI. Key findings were validated via Western blotting, immunofluorescence, and the TOP/FOP flash luciferase reporter assay to monitor Wnt/β-catenin pathway activity.

The use of the Dual Luciferase Reporter Gene System was central for quantifying transcriptional activity changes in the Wnt/β-catenin pathway, with the firefly luciferase substrate reporting pathway activation and Renilla luciferase serving as an internal control for normalization—ensuring robust data quality in gene expression regulation studies.

Protocol Parameters

• Clinical data integration: Analyze TCGA gene expression profiles and validate with immunohistochemistry on at least 3 patient samples.
• Cell transfection for functional assays: Use BCa cell lines (e.g., MCF-7, MDA-MB-231), transfect with CENPI overexpression or knockdown constructs.
• Reporter assay timing: Co-transfect cells with Wnt/β-catenin pathway reporter plasmids (TOP/FOP flash) and control plasmid; measure luciferase activity after 24–48 hours.
• Firefly luciferase substrate: Prepare fresh substrate for each assay to ensure maximal bioluminescence sensitivity.
• Animal studies: Inject manipulated BCa cells into immunodeficient mice and monitor tumor growth over 4–6 weeks.

Core Findings and Why They Matter

The study’s key findings include:

• CENPI is significantly overexpressed in breast cancer tissues and correlates with advanced disease stage and reduced patient survival (Wu et al., 2025).
• CENPI overexpression enhances BCa cell proliferation, migration, and tumor formation in murine xenograft models, while knockdown suppresses these phenotypes.
• Transcriptomic and protein analyses reveal that CENPI upregulation activates canonical Wnt/β-catenin signaling, as evidenced by increased nuclear β-catenin and upregulation of pathway targets. The TOP/FOP flash luciferase assay confirms elevated pathway activity in CENPI-overexpressing cells.
• These results position CENPI as a novel regulator of gene expression regulation in breast cancer, acting upstream of a central oncogenic pathway.

Mechanistically, this work bridges the centromere function with transcriptional regulation study, emphasizing the impact of mitotic regulators on signaling pathways that drive cancer progression. Wnt/β-catenin signaling is a well-established axis in BCa biology, and CENPI’s influence on this pathway expands our understanding of tumor biology and may inform new therapeutic approaches.

Comparison with Existing Internal Articles

Several internal articles, such as "Dual Luciferase Reporter Gene System: High-Throughput Gen..." and "Dual Luciferase Reporter Gene System: Precision in Gene E...", emphasize the critical role of the Dual Luciferase Reporter Gene System (SKU: K1136) in studies of gene expression regulation and high-throughput luciferase detection. These internal resources discuss the lysis-free workflow, sensitivity, and utility in pathway analysis—especially for Wnt/β-catenin signaling, as highlighted in Wu et al. (2025). The reference study leverages similar assay designs, with the dual luciferase system enabling accurate normalization and sensitive detection of transcriptional changes, aligning closely with the practical recommendations from these internal articles. The streamlined workflow and compatibility with standard mammalian cell culture conditions, as covered in internal reviews, support the reproducibility and scalability observed in the reference study.

Limitations and Transferability

While Wu et al. (2025) provide robust evidence for CENPI’s role in breast cancer, several limitations merit consideration. The study’s sample size for human tissue validation is modest, and the findings are primarily specific to breast cancer models; extension to other tumor types or in-depth clinical validation will require further investigation. The focus on Wnt/β-catenin signaling, though mechanistically justified, leaves open questions regarding additional downstream or interacting pathways. As with many preclinical studies, the transferability of results from cell lines and mouse xenografts to patient settings should be interpreted cautiously.

Research Support Resources

Researchers aiming to replicate or expand upon these findings can utilize tools such as the Dual Luciferase Assay System (SKU: K1136) from APExBIO. This system integrates both firefly and Renilla luciferase substrates, enabling sensitive, high-throughput analysis of transcriptional regulation and pathway activity in mammalian cells, as required for Wnt/β-catenin reporter assays. The streamlined, direct-to-cell protocol and robust normalization features make it well-suited for studies in gene expression regulation and bioluminescence reporter assay development. For further scenario-based guidance and troubleshooting, readers may consult internal resources discussing best practices with dual luciferase systems in complex pathway analysis workflows.